1. CpG oligonucleotides (ODNs) have immunostimulatory effects on various subsets of immune cells, and have been used in the treatment of cancer.
2. Strategies to improve the efficacy of CpG ODNs include chemical modification, lipids, G-rich DNA ligands, and encapsulation in gold nanoparticles or hydrogels.
3. Plant virus-like particles (VLPs) are an ideal platform for targeted delivery of therapeutic nucleic acids, and Cowpea chlorotic mottle virus (CCMV)-based VLPs were used to encapsulate CpG-ODN1826 to enhance its antitumor efficacy in two murine tumor models.
The article is generally reliable and trustworthy as it provides evidence for its claims through citations from other sources. The article also presents both sides of the argument equally by discussing potential risks associated with CpG ODN therapy such as local immunostimulation, dose-dependent local reactions, systemic influenza-like symptoms, liver and kidney toxicity, and autoimmune disorders. Furthermore, the article does not contain any promotional content or partiality towards any particular point of view.
However, there are some points that could be improved upon in terms of trustworthiness and reliability. For example, the article does not explore counterarguments or present alternative perspectives on the use of plant viruses for drug delivery or their potential as an in situ vaccine. Additionally, there is no discussion about possible risks associated with using CCMV-encapsulated ODN1826 in vivo such as toxicity or immunogenicity issues that may arise from using a plant virus vector system. Finally, there is no mention of how long the CCMV-encapsulated ODN1826 remains active in vivo or how it is cleared from the body after administration.